Stem-cell mobilization for autografting in chronic myeloid leukemia.
In this article, the rationale for autografting in chronic myeloid leukemia is reviewed, and alternative therapeutic approaches to the use of granulocyte-colony stimulating factor and chemotherapy-mobilized peripheral blood stem cells are discussed. The data from patients treated using the original ICE (idarubicin, cytarabine, etoposide), or the shorter course mini-ICE protocols are considered, with special emphasis on those patients who received their chemotherapy regimens soon after diagnosis and prior to any treatment with interferon alpha. The appropriate design of a trial to test the value of autografting in chronic myeloid leukemia is discussed, as is the optimal timing of collections to achieve the maximal yield and purity of Ph-negative peripheral blood stem cells.
Carella
A M
AM
Hematology and ABMT Unit, Azienda Ospedaliera e Cliniche Universitarie Convenzionate, Ospedale San Martino, Genoa, Italy.
Celesti
L
L
Lerma
E
E
Dejana
A
A
Frassoni
F
F
D000818:Animals; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D014182:Transplantation, Autologous